Letrozole
Product Images NDC 24535-0801

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 24535-0801). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Arab Pharmaceutical Manufacturing Co. Psc Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Letrozole Tablets 01)

Chemical structure diagram of letrozole, showing its molecular framework with a triazole ring connected to two cyanophenyl groups.*

FDA Label Image

Figure 1 Disease-free Survival (median Follow-up 73 Months, Itt Approach) (Letrozole Tablets 02)

Kaplan-Meier survival plot comparing Letrozole and Tamoxifen treatments over 72 months, showing the proportion of patients without events. The chart includes number of patients, events, and censored data for each treatment, with detailed patient counts at risk displayed across specific month intervals.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of Time To Progression (tamoxifen Study) (Letrozole Tablets 03)

A survival curve chart comparing progression-free survival rates over months between Letrozole tablets 2.5 mg and Tamoxifen 20 mg. The x-axis represents time in months up to 60, and the y-axis shows progression-free probability from 0.0 to 1.0.*

FDA Label Image

Figure 3 Survival By Randomized Treatment Arm (Letrozole Tablets 04)

A survival curve graph comparing the proportion of subjects alive over time in months for two groups: one starting treatment with letrozole and the other with tamoxifen. The vertical axis represents survival probability from 0.0 to 1.0, and the horizontal axis shows time from 0 to 60 months.*

FDA Label Image

Figure 4 Kaplan-meier Estimates Of Time To Progression (megestrol Acetate Study) (Letrozole Tablets 05)

A Kaplan-Meier progression-free survival curve displaying time to progression in days for different treatment groups of Letrozole tablets at 0.5 mg and 2.5 mg doses, and an additional group labeled MPA. The vertical axis shows survival probability from 0 to 1.*

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Time To Progression (aminoglutethimide Study) (Letrozole Tablets 06)

A Kaplan-Meier survival curve showing time to progression in days for treatment groups involving Letrozole tablets at 0.5 mg dosage and a group labeled AG. The graph compares progression rates over approximately 1000 days with three distinct lines representing the different groups.*

FDA Label Image

Ndc 24535-0801-1letrozole Tablets, Usp2.5 mgrx Only30 Tablets (Letrozole Tablets 07)

Label for Letrozole Tablets, USP 2.5 mg, containing 30 tablets per container. The label includes storage instructions and states Rx only. Distributed by Arab Pharmaceutical Manufacturing Co. PSC Ltd. The label features the product NDC 24535-0801 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.